Compass Therapeutics (CMPX) Non-Current Assets (2019 - 2026)

Compass Therapeutics (CMPX) has 8 years of Non-Current Assets data on file, last reported at $9.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 29.8% year-over-year to $9.5 million; the trailing twelve-month figure through Mar 2026 stood at $39.9 million (up 59.36% YoY), and the FY2025 full-year result was $9.8 million, up 27.67% from the prior year.
• Non-Current Assets slipped to $9.5 million in Q1 2026, from $9.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $10.5 million in Q2 2025 to a low of $2.1 million in Q2 2024.
• A 5-year average of $6.1 million and a median of $5.7 million in 2022 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets tumbled 47.17% in 2024 and surged 408.62% in 2025, its largest moves.
• Tracing CMPX's Non-Current Assets over 5 years: stood at $4.9 million in 2022, then plunged by 38.32% to $3.0 million in 2023, then surged by 155.58% to $7.7 million in 2024, then rose by 27.67% to $9.8 million in 2025, then declined by 2.93% to $9.5 million in 2026.
• Business Quant data shows CMPX's Non-Current Assets at $9.5 million in Q1 2026, $9.8 million in Q4 2025, and $10.1 million in Q3 2025.